EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines.
Lobo YA, Bonazza C, Batista FP, Castro RA, Bonturi CR, Salu BR, de Cassia Sinigaglia R, Toma L, Vicente CM, Pidde G, Tambourgi DV, Alvarez-Flores MP, Chudzinski-Tavassi AM, Oliva MLV.
Lobo YA, et al. Among authors: salu br.
Cancer Lett. 2020 Oct 28;491:108-120. doi: 10.1016/j.canlet.2020.08.017. Epub 2020 Aug 22.
Cancer Lett. 2020.
PMID: 32841713
Free article.